MEDI 6012

Drug Profile

MEDI 6012

Alternative Names: ACP-501; MEDI-6012; recombinant-lecithin-cholesterol-acyltransferase; rhLCAT - Medimmune

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AlphaCore Pharma
  • Developer AstraZeneca; MedImmune
  • Class Acyltransferases; Antianaemics; Antihyperlipidaemics; Cardiovascular therapies; Enzymes; Recombinant proteins
  • Mechanism of Action Apolipoprotein A I stimulants; Cholesterol modulators; Transferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lecithin acyltransferase deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute coronary syndromes; Atherosclerosis; Coronary artery disease; Myocardial infarction
  • No development reported Adrenal gland disorders; Anaemia; Arterial thrombosis; Lecithin acyltransferase deficiency; Sickle cell anaemia

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Arterial-thrombosis in USA (IV)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Adrenal gland disorders in USA (IV, Infusion)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Anaemia in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top